ArticleMed (New York, N.Y.)2025
A genetic fingerprint associated with durable HIV remission after interruption of antiretroviral treatment: ANRS VISCONTI/PRIMO.
Article in Med (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Trial
- Innate immune imprints shape HIV-1 reservoir cell persistence during long-term antiretroviral therapy.Nature immunology · 2026Article
- Constitutive natural killer cell features associated with post-treatment control of SIV infection in the pVISCONTI study.Nature communications · 2026Article
- Impact of sex differences in adult and paediatric HIV-1 cure.Current opinion in HIV and AIDS · 2026Review
- Natural killer cells in pediatric HIV cure strategies: from viral control to immunotherapeutics.Current opinion in HIV and AIDS · 2026Review
- The elite controller phenotype.Current opinion in HIV and AIDS · 2026Review
- Immune non-response despite effective antiretroviral therapy in people living with HIV: A review of potential mechanisms, biomarkers and therapeutic approaches.HIV medicine · 2026Review
- Post-treatment SIV control is associated with specific features of viral persistence before and after treatment interruption.Nature communications · 2026Article
- Immune correlates of HIV-1 rebound during broadly neutralizing antibody treatment in young children.The Journal of clinical investigation · 2026Article
- Article
- CD8Nature · 2026Article
- Persistent Seronegativity and Absence of Intact Proviruses Despite Prolonged Initial Viremia in Early-Treated Perinatal HIV Infection.Open forum infectious diseases · 2026Article
- Review
- Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection.Current opinion in HIV and AIDS · 2025Review
- Elephant in the room: natural killer cells don't forget HIV either.Current opinion in HIV and AIDS · 2025Review
- Post-intervention control in HIV immunotherapy trials.Current opinion in HIV and AIDS · 2025Review
- Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells.Nature medicine · 2024Article
- Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundThere is currently no curative treatment for HIV-1 infection. However, some individuals (defined as posttreatment controllers) durably control viremia after the discontinuation of antiretroviral therapy (ART). Although the ability to achieve this HIV-1 remission status is enhanced by early treatment initiation, the mechanisms leading to posttreatment HIV-1 control remain unclear.
methodsWe retrospectively explored the immunogenetic characteristics of long-term posttreatment controllers from the ANRS VISCONTI study and persons monitored since primary HIV-1 infection in the ANRS PRIMO cohort and evaluated their influence on clinical parameters and outcome after ART discontinuation.
findingsWe identified a major histocompatibility complex (MHC)-related fingerprint favoring sustained HIV-1 remission. HLA-B∗35 alleles, which are associated with rapid progression to AIDS during natural HIV-1 infection, were paradoxically overrepresented among posttreatment controllers and had a positive impact on outcome after treatment discontinuation in people who began therapy during primary infection. Specifically, the influence of HLA-B∗35 alleles was observed when they were carried in combination with other HLA class I alleles expressing Bw4 and C2 ligands of killer immunoglobulin-like receptors (KIRs) in a genetic context that favors KIR education of natural killer (NK) cells (Bw4TTC2 genotype). Accordingly, posttreatment controllers with HLA-B∗35 alleles carry distinct KIR genotypes and NK cells.
conclusionsThe combination of HLA-B∗35 with Bw4TTC2 genotype, associated with KIR education of NK cells, was abundant among posttreatment HIV-1 controllers and promoted viral control after interruption of early-initiated antiretroviral treatment. These results support a role of NK cells in sustained HIV-1 remission.
fundingThe VISCONTI study and the PRIMO cohort are funded by the ANRS-MIE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.